Respiratory Medicine
Volume 104, Issue 2 , Pages 246-252 , February 2010

Inhaled corticosteroids and risk of pneumonia in newly diagnosed COPD

  • Min J. Joo

      Affiliations

    • Section of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    • Center for Management of Complex Chronic Care (CMC3), Hines VA Hospital, Hines, IL, USA
    • CMC3, Jesse Brown VA Medical Center, Chicago, IL, USA
    • Health Promotion Research, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    • Corresponding Author InformationCorresponding author. 840 S. Wood St. M/C 719, Chicago, IL 60612-7323, USA. Tel.: +1 312 996 8039; fax: +1 312 996 4665.
    • ,
  • David H. Au

      Affiliations

    • Health Services Research and Development, VA Puget Sound Health Care System, Seattle, WA, USA
    • Division of Pulmonary and Critical Care Medicine, University of Washington, Seattle, WA, USA
    • ,
  • Marian L. Fitzgibbon

      Affiliations

    • CMC3, Jesse Brown VA Medical Center, Chicago, IL, USA
    • Health Promotion Research, Department of Medicine, University of Illinois at Chicago, Chicago, IL, USA
    • ,
  • Todd A. Lee

      Affiliations

    • Center for Management of Complex Chronic Care (CMC3), Hines VA Hospital, Hines, IL, USA
    • Department of Pharmacy, University of Illinois at Chicago, Chicago, IL, USA

Received 29 June 2009 ,Accepted 1 October 2009.

References 

  1. Jackevicius CA, Chapman KR. Prevalence of inhaled corticosteroid use among patients with chronic obstructive pulmonary disease: a survey. Ann Pharmacother. 1997;31:160–164
  2. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med. 1999;340:1941–1947
  3. Rascati KL, Stanford RH, Borker R. A comparison of the risk of hospitalizations due to chronicobstructive pulmonary disease in medicaid patients with various medication regimens, including ipratropium, inhaled corticosteroids, salmeterol, or their combination. Clin Ther. 2005;27:346–354
  4. Roche N, Lepage T, Bourcereau J, et al. Guidelines versus clinical practice in the treatment of chronic obstructive pulmonary disease. Eur Respir J. 2001;18:903–908
  5. Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59–65
  6. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Bmj. 2000;320:1297–1303
  7. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775–789
  8. Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102:1099–1108
  9. Gartlehner G, Hansen RA, Carson SS, et al. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006;4:253–262
  10. Kardos P, Wencker M, Glaab T, et al. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007;175:144–149
  11. Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19–26
  12. Ernst P, Gonzalez AV, Brassard P, et al. Inhaled corticosteroid use in chronic obstructive pulmonary disease and the risk of hospitalization for pneumonia. Am J Respir Crit Care Med. 2007;176:162–166
  13. Sobieraj DM, White CM, Coleman CI. Benefits and risks of adjunctive inhaled corticosteroids in chronic obstructive pulmonary disease: a meta-analysis. Clin Ther. 2008;30:1416–1425
  14. Drummond MB, Dasenbrook EC, Pitz MW, et al. Inhaled corticosteroids in patients with stable chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008;300:2407–2416
  15. Sin DD, Tashkin D, Zhang X, et al. Budesonide and the risk of pneumonia: a meta-analysis of individual patient data. Lancet. 2009;374:712–719
  16. Suissa S. Statistical treatment of exacerbations in therapeutic trials of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;173:842–846
  17. Suissa S, Ernst P, Vandemheen KL, et al. Methodological issues in therapeutic trials of COPD. Eur Respir J. 2008;31:927–933
  18. Kelly HW. Comparison of inhaled corticosteroids. Ann Pharmacother. 1998;32:220–232
  19. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl. 2003;41:46s–53s
  20. Seemungal TA, Donaldson GC, Bhowmik A, et al. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–1613
  21. Welte T. Inhaled corticosteroids in COPD and the risk of pneumonia. Lancet. 2009;374:668–670
  22. Syrjala H, Broas M, Suramo I, et al. High-resolution computed tomography for the diagnosis of community-acquired pneumonia. Clin Infect Dis. 1998;27:358–363
  23. Melbye H, Berdal BP, Straume B, et al. Pneumonia – a clinical or radiographic diagnosis? Etiology and clinical features of lower respiratory tract infection in adults in general practice. Scand J Infect Dis. 1992;24:647–655

PII: S0954-6111(09)00323-0

doi: 10.1016/j.rmed.2009.10.002

Respiratory Medicine
Volume 104, Issue 2 , Pages 246-252 , February 2010

Article Tools